Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy
- PMID: 37433280
- DOI: 10.1016/j.ccell.2023.06.004
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy
Abstract
Studies have established immunochemotherapy as the first-line treatment for advanced esophageal cancer. Chen et al. and Carrol et al. performed exploratory analysis of the JUPITER-06 and LUD2015-005 trials, respectively and identified biomarkers to predict therapy response based on immunogenomic analysis. These findings may optimize precise patient stratification in advanced esophageal cancer.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests S. Koyama reports receiving research funding from Otsuka Pharmaceutical and Chugai Pharmaceutical. K.S. reports receiving personal fees for advisory roles from Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Merck Pharmaceutical, Taiho Pharmaceutical, Astellas, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan, and Janssen; honoraria (lecture fees) from Takeda, Bristol-Myers Squibb, and Janssen; and research funding from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Medi Science, Eisai, and Amgen.
Comment on
-
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.Cancer Cell. 2023 May 8;41(5):919-932.e5. doi: 10.1016/j.ccell.2023.03.016. Epub 2023 Apr 13. Cancer Cell. 2023. PMID: 37059106
-
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.Cancer Cell. 2023 Jul 10;41(7):1222-1241.e7. doi: 10.1016/j.ccell.2023.06.006. Cancer Cell. 2023. PMID: 37433281 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
